Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creon 25000 in pancreatic exocrine insufficiency in type 2 diabetes mellitus
2013-001347-31Phase 4Completed
- Sponsor
- Abbott Laboratories
- Start
- Sep 2013
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in exocrine pancreatic insufficiency (EPI) and type 2 diabetes mellitus (T2DM) comparing Creon 25000 with Placebo (2 arms). Primary endpoint: Change in 6-hour 13CO2 cumulative recovery rate (CRR). Started Sep 2013; status: completed.
02
Drugs
pancreatin
03
Conditions
exocrine pancreatic insufficiency (EPI)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-001347-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001347-31.